The invention provides methods and compositions for treating allergies that use antibodies or other products of the immune system from whom have already experienced and responded to an allergen. In particular, people who have suffered from an allergic reaction to an allergen but subsequently become desensitized to the allergen produce immune products that may be isolated or reproduced for use in a therapeutic composition.

In one aspect, antibodies that specifically bind to a phosphorylated Rab protein are provided. In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab10 protein and recognizes an epitope within or comprising the sequence AGQERFH(pT)ITTSYYR (SEQ ID NO:123). In some embodiments, the antibody is a monoclonal antibody that specifically binds to a phosphorylated human Rab8a protein and recognizes an epitope within or comprising the sequence QERFR(pT)ITTAY (SEQ ID NO:125). Methods and materials for detecting LRRK2 and Rab protein are also provided.

The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.

The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.

The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

The present invention provides antibody-based chemically induced dimerizers (AbCIDs) comprising an antibody domain that recognizes a chemical epitope created by the binding of an IMiD to a binding partner, such as cereblon, and methods to rapidly generate such AbCIDs. Several aspects described herein relate to systems, compositions, and methods including components of a chemically induced dimerizer (CID), such as an antibody chemically induced dimerizer (AbCID).

The present invention provides antibody-based chemically induced dimerizers (AbCIDs) comprising an antibody domain that recognizes a chemical epitope created by the binding of an IMiD to a binding partner, such as cereblon, and methods to rapidly generate such AbCIDs. Several aspects described herein relate to systems, compositions, and methods including components of a chemically induced dimerizer (CID), such as an antibody chemically induced dimerizer (AbCID).

A method of producing a therapeutic or preventive antibody for a cancer and/or tumor of interest is disclosed. The methods include binding antibodies of interest to frameshift peptide arrays, selecting frameshift peptides that are immunoreactive to the antibodies, and preparing an antibody composition against the selected frameshift peptides. Also disclosed are antibody compositions, methods of eliciting an immune response and methods of treatment using the methods of producing the antibodies as described herein.

Disclose are methods, compositions and kits for the determination of kidney function that provide an alternative to the standard-of-cure used for eGFR calculations. Described herein are methods for quantitative measurement of ADMA and hydration markers in a urine sample, and process used to transform the input of these methods into a measure of kidney function. The methods allow ADMA and other biomarkers to be detected in urine samples from a subject using a simple and inexpensive assay that can be easily performed noninvasively and only require urine samples for the prediction of kidney function.